Open access · OA via OpenAlex

Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?

Zoe Nicole Memel, Jeffrey Y. Wang, Kathleen E. Corey

Clinical Liver Disease · 2022 · ▲ 26 citations

Dysbiosis Deregulated nutrient-sensing Chronic inflammation Caloric restriction Intermittent fasting Rapamycin / mTOR inhibition Human

＋ Sign in to save

Abstract

Content available: Author Interview and Audio Recording.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: OpenAlex
DOI: 10.1002/cld.1172
Canonical: link ↗
Fetched: 2026-09-28 MST

Cite this

APA

Memel, Z.N., Wang, J.Y., & Corey, K.E. (2022). Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?. <em>Clinical Liver Disease</em>. https://doi.org/10.1002/cld.1172

Vancouver

Memel ZN, Wang JY, Corey KE. Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?. Clinical Liver Disease. 2022. doi:10.1002/cld.1172.

BibTeX

@article{zoe2022Interm, title = {Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?}, author = {Zoe Nicole Memel and Jeffrey Y. Wang and Kathleen E. Corey}, journal = {Clinical Liver Disease}, year = {2022}, doi = {10.1002/cld.1172}, }